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The significant impact of microRNAs (miRNAs) on disease pathology is becoming increas-
ingly evident.These small non-coding RNAs have the ability to post-transcriptionally silence
the expression of thousands of genes. Therefore, dysregulation of even a single miRNA
could confer a large polygenic effect. Schizophrenia is a genetically complex illness thought
to involve multiple genes each contributing a small risk. Large genome-wide association
studies identified miR-137, a miRNA shown to be involved in neuronal maturation, as one
of the top risk genes. To assess the potential mechanism of impact of miR-137 in this
disorder and identify its targets, we used a combination of literature searches, ingenuity
pathway analysis (IPA), and freely accessible bioinformatics resources. Using TargetScan
and the schizophrenia gene resource (SZGR) database, we found that in addition to CSMD1,
C10orf26, CACNA1C,TCF4, and ZNF804A, five schizophrenia risk genes whose transcripts
are also validated miR-137 targets, there are other schizophrenia-associated genes that
may be targets of miR-137, including ERBB4, GABRA1, GRIN2A, GRM5, GSK3B, NRG2,
and HTR2C. IPA analyses of all the potential targets identified several nervous system
(NS) functions as the top canonical pathways including synaptic long-term potentiation, a
process implicated in learning and memory mechanisms and recently shown to be altered
in patients with schizophrenia. Among the subset of targets involved in NS development
and function, the top scoring pathways were ephrin receptor signaling and axonal guidance,
processes that are critical for proper circuitry formation and were shown to be disrupted in
schizophrenia.These results suggest that miR-137 may indeed play a substantial role in the
genetic etiology of schizophrenia by regulating networks involved in neural development
and brain function.
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INTRODUCTION
First discovered in C. elegans (Ruvkun et al., 2004), miRNAs
are small non-coding RNA sequences that play a significant role
in the regulation of gene expression, particularly at the post-
transcriptional level. Regulation by miRNAs is a complex process,
in which some miRNAs are capable of targeting and repressing
hundreds to even thousands of transcripts (Selbach et al., 2008).
Additionally, many mRNAs are targeted by several miRNAs (Sel-
bach et al., 2008; Hu, 2009). It is estimated that the expression of at
least 30% of human genes are regulated by miRNAs (Lewis et al.,
2005; Selbach et al., 2008). With such high levels of potential reg-
ulatory influence, some miRNAs may have enormous impact on
gene expression and such an impact may play a role in the patho-
physiology or etiology of diseases with an elusive genetic basis,
such as schizophrenia. This disease is genetically complex and very
little is understood about its genetic basis or underlying mecha-
nisms (Hamshere et al., 2012). Several recent lines of research
suggest that miRNAs may be involved. First, the gene encoding the
DiGeorge syndrome critical region gene 8 protein (DGCR8), one
of the components of the nuclear miRNA processing complex, is
located in a chromosomal location (22q11.2) associated with high
risk for schizophrenia (Stone et al., 2008). Also, a single-nucleotide
polymorphism (SNP) in the gene for a particular miRNA, miR-
137 was found to be one of the common alleles associated with
schizophrenia (Kwon et al., 2011; Ripke et al., 2011). This report
examines the role of this miRNA in brain development and func-
tion and explores the potential functional impact of its known and
putative targets on schizophrenia. By identifying the putative and
validated miR-137 targets, and examining their potential contri-
bution to functional networks, we hope to shed more light on the
possible role of this miRNA in the etiology of the disease.
microRNA
microRNAs (miRNAs) are small non-coding RNAs with the abil-
ity to silence the expression of multiple target genes by binding to
specific sequences of mRNAs. A single miRNA can impact hun-
dreds to thousands of targets and can affect pathways controlling
a large variety of processes, from normal development to onco-
genesis. Pairing is primarily based on sequence complementarity
of a “seed” sequence within the miRNA to a binding site of the
mRNA, generally in the 3′ UTR of the mRNA being suppressed
(Bartel, 2009). The mechanisms by which miRNAs suppress gene
expression are still not well elucidated; however mRNA destabi-
lization and translational repression have been demonstrated as
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dominant methods of repressing subsequent protein expression
(Carthew and Sontheimer, 2009).
As shown in Figure 1, miRNAs are either first transcribed in
the nucleus as primary miRNAs (pri-miRNAs) or less commonly
spliced from introns (Lin et al., 2006). The pri-miRNAs are then
processed in the nucleus by the microprocessor complex involv-
ing the RNAse III enzyme Drosha complexed with the targeting
protein DGCR8 into approximately 89 nucleotide long sequences
termed pre-miRNAs (Lindow and Gorodkin, 2007; Carthew and
Sontheimer, 2009; Cuperus et al., 2011). Intron derived miRNAs
termed mirtrons are excised by the RNA spliceosomal components
and do not require further processing. These pre-miRNAs are then
exported out of the nucleus by Exportin 5 (Lindow and Gorodkin,
2007) and further processed in the cytoplasm by a protein complex
containing Dicer and its associated proteins the trans-activation
response RNA binding protein (TRBP) and the protein activator
of the interferon induced protein kinase (PACT) into an approx-
imately 22 nucleotide long double stranded RNA (Carthew and
Sontheimer, 2009). These double stranded sequences then sep-
arate and a single strand termed guide strand (mature miRNA)
is loaded with a complementary mRNA into an Argonaute con-
taining microRNA-induced silencing complex (miRISC) where
the miRNA ultimately binds the target sequence (Carthew and
Sontheimer, 2009) to repress ensuing protein expression.
Adenosine deaminases acting on RNA (ADARs) can also
modify and regulate miRNA function, both in the nucleus and
cytoplasm (Figure 1). Adenosine deaminases can modify miRNA
processing and function not only by editing pri- and pre-miRNA
sequences but also through steric hindrance in the absence of RNA
editing (Heale et al., 2009). Alterations in miRNA sequence can
lead to shifted (Kawahara et al., 2007), reduced, or eliminated
targeting or reduction in mature miRNA production (Luciano
et al., 2004). ADAR miRNA editing seems to play an impor-
tant role in mammalian brain development (Ekdahl et al., 2012).
Surprisingly, very few studies have addressed the potential role
of ADAR mRNA editing in psychiatric illness, with conflict-
ing results (Silberberg et al., 2012; Zhu et al., 2012). However,
given that the studies only addressed mRNA editing effects, there
may be an alternative large scale regulatory impact of ADARs
on miRNA regulation of gene expression, which remains to be
explored.
SCHIZOPHRENIA AND miRNAs
Schizophrenia is a severe mental illness that has an average lifetime
development risk of 0.7%, with an average annual incidence rate
of 15 per 100,000 (Tandon et al., 2008; Blanchard et al., 2011).
Heritability of the disease is estimated at 81% based on twin stud-
ies (Sullivan et al., 2003). The term schizophrenia meaning, “split
mind” was coined by Bleuler in 1911 to describe the dissociation
of thought, ideas, identity, and emotion that characterize the ill-
ness (Moskowitz and Heim, 2011). The disease is described by
negative symptoms of social withdrawal, positive symptoms of
FIGURE 1 | MicroRNA biogenesis and function. MicroRNAs (miRNA) are
generated via the mirtron or canonical pathway. Primary microRNA
(pri-miRNA) from the canonical pathway is further processed by the
Drosha-DGCR8 complex into precursor miRNA (pre-miRNA). Pre-miRNAs
derived from both pathways are then exported from the nucleus by Exportin
5. In the cytoplasm, this pre-miRNA is further processed by the
Dicer/TRBP/PACT complex into a duplex miRNA. One of the strands (guide
strand or mature miRNA) is then loaded into the miRISC complex along with
the target mRNA. Depending on the degree of sequence complementary,
miRNAs lead to translational repression, deadenylation, or degradation of
the target mRNAs, all reducing downstream protein expression. Adenosine
deaminases acting on RNA (ADARs) may inhibit various steps of miRNA
processing thus reducing or shifting miRNA function. See text for more
detail.
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psychosis including hallucination and delusion, cognitive impair-
ment, and in some cases mood dysregulation (van Os and Kapur,
2009). These symptoms lead to secondary disparities in health and
premature mortality, stressing the need for better understanding
of the underlying mechanisms.
This mental illness is largely heterogenetic, with different
patients having different associated genetic alterations and var-
ied symptomology (Sebat et al., 2009; Green et al., 2012; Wahlsten,
2012). Evidence also suggests that it is a polygenic disorder, in
which many common genetic variants may each contribute a small
increased risk (Purcell et al., 2009). Given this evidence for such
polygeneity and the fact that single miRNAs have the potential
to regulate hundreds to thousands of transcripts (Selbach et al.,
2008), it seems plausible that disruption of a miRNA could lead to
abnormal expression levels of many genes, which could in turn
contribute to schizophrenia vulnerability. Many miRNAs were
found to be differentially expressed in blood samples and post-
mortem tissue of patients with schizophrenia (Perkins et al., 2007;
Beveridge et al., 2010; Kim et al., 2010; Gardiner et al., 2011; Lai
et al., 2011; Moreau et al., 2011; Santarelli et al., 2011; Miller et al.,
2012) providing further evidence that miRNAs may impact the
disorder.
One miRNA of particular interest is hsa-miR-137. The recent
study from The Schizophrenia Psychiatric Genome-Wide Asso-
ciation Study (GWAS) Consortium (Ripke et al., 2011), with an
initial sample size of 21,856 and a replication sample of 29,839
found several new significant loci to be associated with schizo-
phrenia, the strongest association being the SNP rs1625579 within
an intron containing the primary transcript of miR-137. Several
of the other associated loci contained predicted targets of miR-
137 (Ripke et al., 2011) supporting evidence that miR-137 might
play a role in the disorder. A subsequent smaller GWAS study
examining a smaller sample of patients with treatment-resistant
schizophrenia from the UK receiving clozapine treatment, also
found significant association for CACNA1C but did not replicate
the finding for CSMD1 or miR-137, yet when the data was grouped
with the earlier GWAS study both were found to be significant
(Hamshere et al., 2012).
Besides GWAS studies, two additional experimental approaches
are beginning to shed light onto the possible link between miR-
137 and schizophrenia. First, using luciferase reporter assays, Kwon
et al. (2011) confirmed that transcripts of other genes associated
with schizophrenia in the largest GWAS study (Ripke et al., 2011),
namely CSMD1, C10orf26, CACNA1C, and TCF4 can in fact be
regulated by miR-137. Likewise, Kim et al. (2012) recently demon-
strated that ZFN804A another gene highly associated with the
illness (O’Donovan et al., 2008; Steinberg et al., 2011) can also be
silenced by miR-137 in vitro. While further research is required
to confirm the association of the SNP in miR-137 with risk for
schizophrenia, the findings that miR-137 can regulate the expres-
sion of other schizophrenia-associated genes provides new clues
on how miR-137 may play a role in the illness. Along these lines,
a recent post-mortem tissue study suggests that the T risk allele
of rs1625579 may be associated with decreased miR-137 expres-
sion in the dorsolateral prefrontal cortex of patients (Guella et al.,
2012), further suggesting a potential dysregulation of the miRNA’s
targets.
ROLE OF miR-137 IN BRAIN DEVELOPMENT AND FUNCTION
miR-137 is expressed in embryonic and adult brains (Sun et al.,
2011) and was found to be highly enriched in synaptosomes from
P15 rats (Siegel et al., 2009). Using in situ hybridization, high
expression of this microRNA was observed in the dentate gyrus,
an area highly active in adult neurogenesis (Smrt et al., 2010).
The involvement of this miRNA in neuronal development was
confirmed by several functional experiments. Overexpression of
miR-137 was shown to decrease proliferation of mouse embryonic
neural stem cells leading to their premature neuronal differentia-
tion (Sun et al., 2011) and similar effects were observed in adult
mouse neural stem cells derived from the subventricular zone or
from brain tumors (Silber et al., 2008). However, overexpression of
miR-137 in the adult neural stem cells derived from the subgran-
ular layer of the dentate gyrus was found to disrupt the expression
of stage specific differentiation markers such as DCX and NeuN
as well as dendritic arborization in these newly generated neu-
rons (Smrt et al., 2010). This apparent discrepancy is likely due
to distinct roles of miR-137 in different stages of neuronal differ-
entiations as well as the intrinsic properties of cells in different
neurogenic zones. In a recent study, overexpression of miR-137
was shown to decrease maturation and increase proliferation while
antagonism of miR-137 in adult neural stem cells increased neu-
ronal differentiation and reduced proliferation (Szulwach et al.,
2010). These experiments suggest that a balanced expression of
miR-137 is necessary to maintain appropriate neuronal differenti-
ation and proliferation and thus regulate neurogenesis. Given the
important role that neurogenesis plays in learning, memory, and
mood regulation, disruption of these essential functions may have
significant effects that could lead to some of the symptomology
seen in schizophrenia (DeCarolis and Eisch, 2010).
ASSOCIATION OF miR-137 AND COGNITIVE FUNCTION
Recent genetics imaging studies have also found a correlation of
miR-137 with schizophrenia. Firstly, utilizing gene set enrichment
analysis to assess the contribution of gene regulatory networks to
the illness, Potkin et al. (2010) found that miR-137 was implicated
in two individual GWAS imaging genetics studies of patients per-
forming the Sternberg item recognition paradigm (SIRP) working
memory task (Potkin et al., 2009a,b). Given the findings of the
large 2011 GWAS study (Ripke et al., 2011), a subsequent study
examining subjects at risk for schizophrenia and bipolar disor-
der differentiated their cohorts based on this SNP (Whalley et al.,
2012). Subjects with two copies of the “T” risk allele were assigned
as risk positive and those carrying one or no copies of the allele
were classified as risk negative subjects. A reduced response in the
right posterior medial frontal gyrus region to increasingly diffi-
cult sentence completion tasks was noted only in the risk positive
group across all the groups: schizophrenia at risk, bipolar at risk,
and controls. This suggests that miR-137 may have a general effect
on executive function. Also, schizophrenia at risk subjects had dif-
ferential activation of the left amygdala and left pre/postcentral
gyrus, suggesting a more schizophrenia-specific effect of the allele
as well (Whalley et al., 2012).
Recent studies also examined the role of this miRNA on other
functional endophenotypes. The risk allele in miR-137 was poten-
tially associated with the P300 endophenotype in schizophrenia
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patients (Decoster et al., 2012). In addition, when combined with
greater negative symptoms, the rs1625579 SNP genotype pre-
dicted membership of patients in a subgroup with severe cognitive
deficits (Green et al., 2012). In this study, cognitive functioning was
evaluated by a battery of tests such as the Letter-Number Sequenc-
ing Test to assess working memory, and the Controlled Oral Word
Association Test to assess executive function. First patients were
categorized based on their performance with this battery of tests
into either a cognitive deficit group or a cognitive spared group.
Patients with more severe negative symptoms and the “G” pro-
tective allele were surprisingly more likely to have been previously
grouped in the cognitive deficit group (Green et al., 2012). Another
study examining carriers of the risk allele among psychosis
patients, including those with schizophrenia, schizoaffective disor-
der and bipolar affective disorder I, found that carriers,particularly
those homozygous for the “T” risk allele, had lower scores for psy-
chotic symptoms and a subtle deficit in performance of episodic
memory and attention control tasks (Cummings et al., 2013).
While studying the clinical effects of chromosome 1p21.3
microdeletions, the region containing the MIR-137 gene, Willem-
sen et al. (2011) found an association with intellectual disability
and autism disorder spectrum-like behavior. Furthermore, lym-
phoblastoid cell lines from these patients were found to have
reduced levels of miR-137 and enhanced levels KLF4 and the pre-
viously verified target genes MITF and EZH2. The authors also
confirmed that miR-137 is highly expressed in the hippocampus,
occipital cortex, and frontal cortex in human post-mortem tissue,
as well as in the synaptosomal fractions in mouse brain prepara-
tions, providing further evidence that miR-137 may play a role in
synapse formation during brain development and function.
TARGETS OF miR-137
To further understand the possible mechanism of miR-137 in
schizophrenia, we used available databases and the literature to
identify putative and validated targets. Using the list of potential
and experimentally verified targets, we then evaluated their chro-
mosomal location and temporal patterns of expression. Finally,
we examined how these targets cluster within biological pathways
to identify which functions would be affected if miR-137 levels
were dysregulated as shown by initial post-mortem tissue studies
(Guella et al., 2012).
PUTATIVE TARGETS
Putative targets were identified by querying the publically available
TargetScan Human release 6.2 database updated June 2012 for hsa-
miR-137 (Friedman et al., 2009). Selecting for target genes respec-
tive to site conservation resulted in 1144 putative target genes.
The Ensemble cytoband location for each gene was identified by
querying for each gene offered in the freely available GeneCards
encyclopedia at www.genecards.org (Stelzer et al., 2011) (Table
S1 in Supplementary Material). All subsequent analyses were per-
formed using this list, as TargetScan offers several advantages over
other target prediction algorithms given its unique considera-
tion for sequence context in addition to conservation and seed
sequence complementarity (Grimson et al., 2007; Friedman et al.,
2009). This list was then evaluated to identify targets studied for
experimental validation in the following section.
Examining genes that may play a role in schizophrenia, we com-
pared our putative target lists against a schizophrenia-associated
gene list of 278 protein-coding genes from the publicly available
schizophrenia gene resource (SZGR), a database of a variety of
schizophrenia related gene lists (Jia et al., 2010). We chose to use
the association studies gene list that is derived from the Schizo-
phreniaGene (SZGene) database and further evaluated for consis-
tency across studies using a combined odds ratio (OR) method
(Sun et al., 2008). Of the 1144 TargetScan putative target list, 25
genes intersected with the SZGR schizophrenia-associated gene
list. These genes are listed in Table 1, including cytoband location
Table 1 | SZGR associated miR-137 target genes*.
Gene symbol Full name Cytoband
ACSL6 Acyl-CoA synthetase long-chain family
member 6
5q31.1
ATXN1 Ataxin 1 6p22.3
BRD1 Bromodomain containing 1 22q13.33
C18orf1 Chromosome 18 open reading frame 1 18p11.21
CHGA Chromogranin A (parathyroid secretory
protein 1)
14q32.12
ERBB4 V-erb-a erythroblastic leukemia viral
oncogene homolog 4 (avian)
2q34
FOXP2 Forkhead box P2 7q31.1
FXYD6 FXYD domain containing ion transport
regulator 6
11q23.3
FZD3 Frizzled homolog 3 (Drosophila) 8p21.1
GABRA1 Gamma-aminobutyric acid (GABA) A
receptor, alpha 1
5q34
GRIA1 Glutamate receptor, ionotropic, AMPA 1 5q33.2
GRIA4 Glutamate receptor, ionotropic, AMPA 4 11q22.3
GRIN2A Glutamate receptor, ionotropic,
N -methyl-d-aspartate 2A
16p13.2
GRM5 Glutamate receptor, metabotropic 5 11q14.3
GSK3B Glycogen synthase kinase 3 beta 3q13.33
HTR2C 5-Hydroxytryptamine (serotonin) receptor 2C Xq23
IMPA2 Inositol(myo)-1(or 4)-monophosphatase 2 18p11.21
MLC1 Megalencephalic leukoencephalopathy with
subcortical cysts 1
22q13.33
NRG2 Neuregulin 2 5q31.2
NRG3 Neuregulin 3 10q23.1
PLXNA2 Plexin A2 1q32.2
SYN2 Synapsin II 3p25.2
SYN3 Synapsin III 22q12.3
TNXB Tenascin XB; tenascin XA pseudogene 6p21.33
TSNAX Translin-associated factor X 1q42.2
*This list is derived from the intersection of the 1144TargetScan putative target list
with the SZGR schizophrenia-associated gene list. Cytoband location information
was identified using GeneCards.
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information identified from GeneCards. Estimating that there are
20,000 genes in the genome, and that 278 are considered risk genes
for schizophrenia, the probability that a randomly chosen sample
of 1144 genes contains 25 or more of these risk genes is 0.017.
Therefore, this result suggests that miR-137 targets are enriched in
schizophrenia risk genes.
EXPERIMENTALLY VERIFIED TARGETS
Twenty-six experimentally verified targets were identified using
the publicly available database TarBase (Vergoulis et al., 2012) and
manual literature searches (Table 2). The functional targeting of
these targets by miR-137 was confirmed by luciferase expression
reporter and Western blot assays in a variety of cell lines. A PubMed
search of miR-137 resulted in 44 articles, 16 of which had abstracts
mentioning target gene validation experiments, which were fur-
ther evaluated for their relevance. Only targets reported in articles
using functional validation assays were included except for KLF4,
which was confirmed by qPCR in an animal model over-expressing
miR-137 (Willemsen et al., 2011). A subsequent search of hsa-miR-
137 yielded no more unique articles from the previous search. Of
note, ZNF804A, a gene implicated in schizophrenia in several stud-
ies (O’Donovan et al., 2008; Steinberg et al., 2011; Walton et al.,
Table 2 | Experimentally verified targets of hsa-miR-137.
Verified target Assay Cell lines Reference Source
CTBP1 Ago2 binding assay, luciferase assay HEK293, A375 Deng et al. (2011) TarBase
CDC42 Western blot, luciferase assay SW116, Lovo, Hela, AGS, MKN45 Liu et al. (2011), Chen et al.
(2011a)
TarBase
CDK6 Luciferase assay, Western blot U251, OSCC, HEK293 Silber et al. (2008), Kozaki et al.
(2008), Chen et al. (2011b)
TarBase
KDM1A (LSD1) Luciferase assay, Western blot HCT116, HEK293, neural stem
cells
Balaguer et al. (2010), Sun et al.
(2011)
TarBase,
Literature search
E2F6 Western blot OSCC Kozaki et al. (2008) TarBase
NCOA2 Western blot OSCC Kozaki et al. (2008) TarBase
MITF Luciferase assay, GFP reporter HEK293, A375, WM852 Haflidadóttir et al. (2010), Chen
et al. (2011b), Bemis et al. (2008)
Literature search
KDM5B (Jarid1b) Western blot, luciferase assay mouse ESC, HEK293 Tarantino et al. (2010) Literature search
SPTLC1 Luciferase assay rat primary astrocytes Geekiyanage and Chan (2011) Literature search
PTBP1 Luciferase assay Neuro2a cells Smith et al. (2011) Literature search
CSMD1# Luciferase assay HEK-293T Kwon et al. (2011) Literature search
C10orf26# Luciferase assay HEK-293T Kwon et al. (2011) Literature search
CACNA1C# Luciferase assay HEK-293T Kwon et al. (2011) Literature search
TCF4# Luciferase assay HEK-293T Kwon et al. (2011) Literature search
CDK2 Western blot M23 and SP6.5 Chen et al. (2011b) Literature search
RB1 (p-Rb) Western blot M23 and SP6.5 Chen et al. (2011b) Literature search
MAPK1 (p-ERK1/2) Western blot M23 and SP6.5 Chen et al. (2011b) Literature search
MAPK3 (p-ERK1/2) Western blot M23 and SP6.5 Chen et al. (2011b) Literature search
MET (c-Met) Western blot M23 and SP6.5 Chen et al. (2011b) Literature search
ESRRA Luciferase assay HepG2 Zhao et al. (2012) Literature search
PTGS2 (Cox-2)* Western blot, luciferase assay U87 and LN229 Chen et al. (2012) Literature search
MIB1 Luciferase assay DIV6 primary neurons Smrt et al. (2010) Literature search
MSI1 Western blot, luciferase assay U251, Daoy, HeLa Vo et al. (2011) Literature search
EZH2 Luciferase assay HEK-293T Szulwach et al. (2010) Literature search
KLF4 Quantitative reverse transcription
PCR in over-expressing miR-137
animal model
LCL Willemsen et al. (2011) Literature search
ZNF804A# Luciferase assay HEK-293T, Be2C Kim et al. (2012) Literature search
*Indicates genes in SZGR associated list.
#Indicates genes associated with schizophrenia but not in SZGR list.
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2012) was experimentally verified (Kim et al., 2012) although it
was not included in the TargetScan putative target list, presumably
because of the poor conservation of its binding site.
CHROMOSOMAL LOCATION OF TARGET GENES
Cytoband data was gathered from the UCSC database table
browser, assembly dated February 2009, http://genome.ucsc.edu/
(Karolchik, 2004). miR-137 target gene location data was identi-
fied using the GeneCards database. This data was graphed using
the Matlab Bioinformatics Toolbox (Figure 2). Target genes are
located throughout the genome with a few localized “hot spots”
(shown by red vertical lines in the figure). There are several
“hotspots” located in Chromosomes 1, 11, 12, 16, and one each
in chromosome 3, 14, 17, 19, and X. Comparison of the cytoband
locations with miR-137 targets and those known to be affected
by copy number variations (CNVs) in schizophrenia and autism
spectrum disorders (ASD) (Liu et al., 2012; Sullivan et al., 2012)
revealed several regions of overlap (see cytobands shown in red
in Table S1 in Supplementary Material). While the proportion of
overlapping cytobands did not reach global statistical significance
with a hypergeometric probability test, it is important to note
that one of these regions mapped to NRXN1, a 2p16.3 gene with
associated deletions both in schizophrenia and ASD and whose
transcript is a putative miR-137 target.
FUNCTIONAL RELEVANCE OF TARGET GENES
EXPRESSION OF TARGET GENES
Given that the onset of schizophrenia generally occurs in ado-
lescence and early adulthood, we reviewed the temporal expres-
sion patterns of miR-137 target genes. Using the freely available
BrainCloud expression database developed by the Lieber Institute
for Brain Development (LIBD) and the National Institute of
Mental Health (NIMH) (Colantuoni et al., 2011) that uses the
expression profiles in the dorsolateral prefrontal cortex of human
post-mortem tissue across the lifespan, we examined the expres-
sion patterns of all available experimentally verified target genes
(Table 2) and putative targets common to the SZGR association list
(Table 1). Except for ATXN1, CDC42, GRIN2A, KDM1A (LSD1),
and SYN3 we found expression patterns for all these genes. Of
the 46 examined genes, about 41% have peak expressions dur-
ing prenatal life, 13% during prenatal and post-natal combined,
20% post-natal, 4% both post-natal and adult, and 22% during
adulthood (Figure 3). Comparison of the patterns of expression
of miR-137 targets vs. whole brain transcriptome (Kang et al.,
2011) revealed that the targets have an atypical temporal distri-
bution with peak expressions occurring more often during the
prenatal period, or during adult life. The findings that 74% of
target genes have peak expressions prior to adulthood, particu-
larly prenatally, suggest that these target genes may be particularly
relevant to the development of the schizophrenia. The unexpect-
edly large proportion of genes with peak expression in adulthood
raises the possibility that miR-137 targets are involved in the ongo-
ing decline in cognitive function and gray matter density observed
in schizophrenia over the lifespan.
PATHWAY ANALYSIS
Pathway analysis was performed using the putative target gene
list derived from TargetScan, containing 1144 target genes and
the 8 experimentally verified target genes (Table 2) not con-
tained within the putative list. This analysis was performed in
FIGURE 2 | miR-137 target gene locations. Karyotype representing cytoband locations of the miR-137 TargetScan putative target genes. Blue depicts
cytobands with two to five target genes. Red indicates regions containing six or more target genes.
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FIGURE 3 | Peak expression life stage for genes of interest. Temporal
expression data for all available miR-137 putative targets and verified
targets is based on the BrainCloud Database (Kang et al., 2011).
Comparison of the temporal expression profiles of miR-137 targets and
whole brain transcriptome (BrainCloud) using Chi square analysis revealed
that the temporal expression profile frequency distributions were
significantly different (p<0.01). The prenatal stage is defined as week 14
through birth, post-natal stage is defined as birth through age 20 years, and
adult stage is defined as age 20 years and older.
three levels using the Ingenuity Pathway Analysis (IPA) software
(Ingenuity®Systems, CA, USA, www.ingenuity.com) generating a
canonical pathway analysis and related network analyses for each
level. The networks are given a score based on the probability of
inclusion of the number of molecules in the generated networks
over the probability of a network being generated by chance with
random molecules. This score is generated as a negative log p
value based on a right tailed Fisher’s exact test (Calvano et al.,
2005). Canonical pathway analysis is performed by comparing the
dataset of interest against known canonical (signaling and meta-
bolic) pathways within the database. A negative log p value is also
assigned to the pathways based on a Fisher’s exact test of the prob-
ability of the number of molecules from the user-created dataset
included in the given pathways vs. being included based on chance
alone.
A core analysis was first performed with this data set analyzing
molecules in all tissue types in mammals. Of the 1144 putative
target genes, 1142 were mapped in the IPA software and usable
for the analysis. In addition the eight experimentally verified tran-
scripts not included in this putative target list were all mapped
in IPA and included in the analysis, so that a total of 1150 target
genes were used in the analysis. The top scoring canonical path-
ways corresponding to targets expressed (a) in all tissues, (b) only
in the nervous system (NS), or (c) those associated with NS devel-
opment and function are shown in Figure 4. Interestingly, while
Sertoli cell-signaling (Figure S1 in Supplementary Material) was
the top scoring pathway for targets expressed in all tissues, this set
also included several NS-specific pathways. Among these, the top
scoring pathways were agrin interaction at the neuromuscular junc-
tion (Figure S2 in Supplementary Material), and synaptic long-term
potentiation (LTP) (Figure S3 in Supplementary Material). The top
physiological system associated with miR-37 targets, containing
FIGURE 4 | IPA canonical pathway analyses from each tier of core
analysis. The X axis represents negative log p values based on the
probability that molecules in the uploaded dataset were included the
predefined IPA canonical pathways by true association as opposed to
inclusion of molecules based on chance alone. Pathways not involved in
nervous system were removed from the nervous system tissue analysis
and nervous system development and function graphical displays. Only the
top 10 pathways with the largest negative log p values are shown. The
dashed line indicates the threshold of significance for a p value of 0.01.
GNRH, gonadotropin-releasing hormone; HGF, hepatocyte growth-factor;
NMJ, neuromuscular junction.
202 genes, was NS development and function. Using this set, we
found that the top pathways were ephrin receptor signaling (Figure
S4 in Supplementary Material), and axonal guidance (Figure S5
in Supplementary Material), processes known to be involved in
neuronal development and cognition.
The biological significance of the molecules included in these
canonical pathways is best illustrated by their associated interactive
networks (Figures 5–7). As shown in Figure 5, the top networks
of targets expressed in all tissues contained a large number of NS
associated molecules, depicted in yellow, confirming past studies
that miR-137 is involved in NS development (Silber et al., 2008;
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FIGURE 5 |Top 3 scoring IPA network analysis generated networks for all
mapped 1150TargetScan putative targets and verified targets. The top 3
scoring networks identified were: (A) “hereditary disorder, neurological
disease, skeletal and muscular disorders,” with a score of 39, (B) “cellular
development, connective tissue development and function, cancer,” with a
score of 39, and (C) “protein synthesis, endocrine system development and
function, and lipid metabolism,” with a score of 36. Yellow indicate molecules
expressed in the nervous system. White molecules are those not included in
the uploaded dataset but added by IPA. Gray molecules indicate those that
were included in the uploaded dataset. Relationships depicted by lines with
arrows represent “act on,” while lines without arrows represent binding. See
figure keys for identification of the types of molecules included.
Siegel et al., 2009; Smrt et al., 2010; Szulwach et al., 2010; Sun
et al., 2011). A subsequent core analysis was then performed with
the 929 NS tissue associated subset of molecules of the origi-
nal 1150 putative and verified target genes used in the previous
analysis. This resulted in networks (Figure 6) including a substan-
tial number of target genes found in the SZGR database and the
experimentally verified list, as well as many other schizophrenia-
associated genes. Finally, the top association networks of targets
involved in NS development and function also contained many of
the schizophrenia-associated and verified target genes (Figure 7).
CONCLUSIONS AND PERSPECTIVES
There is evidence that schizophrenia is a highly complex poly-
genic disorder with multiple genes contributing only a small risk.
Given that individual miRNAs can affect the expression of up
to thousands of genes post-transcriptionally, and that differential
expression of miRNAs between patients with schizophrenia and
controls has been shown in many different studies; it seems likely
that miRNAs may play a role in the etiology of the disease. miR-137
in particular was shown to have a SNP (rs1625579) with the highest
association with schizophrenia in the largest schizophrenia GWAS
study performed to date (Ripke et al., 2011). Although the mech-
anisms by which this SNP may cause a dysregulation in miR-137
processing is not completely understood, recent studies suggest
that carriers of the risk allele have abnormal levels of mature miR-
137 in the cerebral cortex (Guella et al., 2012). Considering the
biological pathways associated with miR-137 targets, there are sev-
eral possible mechanisms, discussed below, by which alterations
in miR-137 expression may contribute to the development and
pathophysiology of schizophrenia.
Imaging genetics studies have shown an association of the miR-
137 risk allele with reduced fMRI responses in both patients and
at risk subjects while performing cognitive tasks (Potkin et al.,
2009a,b, 2010; Whalley et al., 2012). In addition, this SNP was
also shown to have a potential association with the P300 endophe-
notype (Decoster et al., 2012) and a significant association with
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FIGURE 6 |Top 3 scoring IPA network analysis generated networks for
the 929 nervous tissue specific putative and verified targets. The top 3
scoring networks identified by this analysis were: (A) “hereditary disorder,
neurological disease, skeletal and muscular disorders,” with a score of 35, (B)
“neurological disease, cell-to-cell signaling and interaction, nervous system
development and function,” with a score of 10, and (C) “behavior, cell-to-cell
signaling and interaction, nervous system development and function,” with a
score of 8. White molecules are those not included in the uploaded dataset
but added by IPA. Gray molecules indicate those that were included in the
uploaded dataset. Relationships depicted by lines with arrows represent “act
on,” while lines without arrows represent binding. See figure legend keys for
identification of the types of molecules included. Blue outlines depict
experimentally validated targets and those in red indicate SZGR associated
targets.
cognitive deficits in patients with schizophrenia using a variety of
tasks (Green et al., 2012; Cummings et al., 2013). Furthermore, a
recent study (Lett et al., 2013) found that the risk allele was associ-
ated with earlier age-at-onset of psychosis, decreased hippocampal
volume, and reduced white matter integrity throughout the entire
brain. Given that miR-137 plays a role in neurogenesis, neurode-
velopment, dendritic arborization, and is located in the synapse
(Silber et al., 2008; Siegel et al., 2009; Smrt et al., 2010; Szulwach
et al., 2010; Sun et al., 2011) it is enticing to propose that abnormal
expression of this miRNA may lead to abnormal synapse for-
mation which could in turn play a role in the cognitive deficits,
psychotic symptoms, and brain structural abnormalities found in
these patients.
By utilizing the freely accessible TargetScan, GeneCards, and
UCSC databases, we found that the miR-137 potentially targets
over a thousand genes, with a variety of functions and potential
impact. As depicted in Figure 2 these putative target genes can
be found throughout nearly every chromosome, with some par-
ticular regions of high concentration. This list of putative target
genes also includes some known to be associated with schizo-
phrenia (e.g., ERBB4, GABRA1, GRIN2A, GRM5, GSK3B, NRG2,
and HTR2C) as well as many experimentally verified as true
targets. Subsequent analysis of these putative and verified genes
using IPA demonstrates that this list of genes includes many NS-
specific genes. Expression Data from BrainCloud also confirms
that many of the genes such as FXYD6, BRD1, GSK3B, CDK6,
CDC42, and CACNA1C have higher expression levels in onset risk
time periods, suggesting their relevance in contributing risk for
development of schizophrenia. These target genes also form net-
works involved in neuronal function and development; with the
top canonical pathways associated being agrin interaction at the
neuromuscular junction, synaptic LTP, ephrin receptor signaling, and
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FIGURE 7 |Top 3 scoring IPA network analysis generated networks for
202 nervous system development and function subset of putative and
verified targets. The three top scoring networks identified were: (A)
“behavior, hereditary disorder, neurological disease,” with a score of 29, (B)
“cell morphology, cellular assembly and organization, cellular development,”
with a score of 12, and (C) “cell-to-cell signaling and interaction, nervous
system development and function, neurological disease,” with a score of 10.
White molecules are those not included in the uploaded dataset but added
by IPA. Gray molecules indicate those that were included in the uploaded
dataset. Relationships depicted by lines with arrows represent “act on,”
while lines without arrows represent binding. See figure keys for
identification of the types of molecules included. Blue outlines depict
experimentally validated targets and those in red indicate SZGR associated
targets.
axonal guidance signaling (Figures S2–S5 in Supplementary Mate-
rial). Sertoli cell-signaling (Figure S1 in Supplementary Material)
was the top scoring pathway identified by the first tier of analysis
of all 1150 putative and verified targets of miR-137, which may
be related to the increased risk of schizophrenia with increasing
paternal age (Frans et al., 2011). The identification of agrin inter-
action at neuromuscular junctions as a top canonical pathway may
also be of interest given the association with neurological soft signs
and schizophrenia (Sewell et al., 2010). Also, given that several of
the same target transcripts play a role in cell–cell interactions in
the periphery and the CNS, it is likely that this miRNA has sim-
ilar roles in other tissues. However, given the enrichment of this
mRNA in developing neurons, we focus our discussion in this
cell type.
Many of the top scoring pathways identified: LTP signaling,
ephrin receptor signaling, and axonal guidance signaling, are
closely linked to learning and memory and have shown to be
associated with schizophrenia. A recent study suggests evidence of
impaired LTP in schizophrenia patients with a simultaneous deficit
in motor learning (Frantseva et al., 2008). In addition, many schiz-
ophrenia animal model studies have also demonstrated an impair-
ment of LTP (Pollard et al., 2012). Of particular interest, a study
examining ERBB4 (one of the miR-137 putative target genes), and
synaptic potentiation, demonstrated that mice with a full ErbB4
knock-out and mice with a conditional ErbB4 knock-out in only
parvalbumin expressing cells exhibit increased hippocampal LTP
and lack theta-pulse evoked LTP reversal (Shamir et al., 2012).
These mice have increased locomotor activity in the open field test;
such hyperactivity in response to novelty is used often as a model of
positive symptomatology in schizophrenia. The mice also exhibit
deficits in prepulse inhibition of the acoustic startle response, a test
believed to model sensorimotor gating, which has been shown to
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be reduced in patients with schizophrenia. These findings provide
further evidence that miR-137 may indeed impact LTP in schiz-
ophrenia leading to the cognitive dysfunction, a clinical feature
still poorly understood and inadequately treated (Blanchard et al.,
2011).
Axonal guidance has also been implicated in schizophrenia.
Ephrin signaling plays a role in axonal guidance by controlling
axon motility (Xu and Henkemeyer, 2012). A recent imaging
study found an association between polymorphisms in RELN and
PCDH12, genes involved in neuronal guidance and synaptic for-
mation, and alterations in the patients’ brain structure as seen by
MRI (Gregório et al., 2009). Another imaging study found an asso-
ciation with SNPs in RELN, PLXNA2, and other genes involved
in axonal guidance and neuronal development and prediction of
DLPFC inefficiency during a working memory task (Walton et al.,
2012). There is also evidence linking ephrin receptor signaling and
LTP. Particularly two studies found that post-synaptic EphB recep-
tors and presynaptic B-ephrins are necessary for the induction
of LTP of the mossy fibers in the hippocampus, a N -methyl-d-
aspartate (NMDA) receptor independent form of LTP (Contractor
et al., 2002; Armstrong et al., 2006). Of note, many genes involved
in glutamate signaling such as GRIA1, GRIA4, GRIN2A, GRM2,
and GRM5 were identified in the generated networks and were
included in the LTP signaling cascade of the IPA canonical pathway
(Figure S3 in Supplementary Material). The potential role of miR-
137 in the expression of these glutamate receptors could explain
not only the altered glutamate signaling observed in schizophrenia
(Coyle, 2006; Sendt et al., 2012), but also the LTP disruption in the
illness, which may in turn contribute to the associated cognitive
deficits.
Interestingly, we also found that the Huntington’s associated
protein Huntingtin (HTT) was identified as a hub in all three
tiers of IPA network analyses. While the normal function of this
protein is still largely unknown, it is possible that HTT has been
included in the IPA database as having many biological relation-
ships largely because it is well studied. However, recent evidence
suggests that HTT is involved highly in neuronal development,
playing a role in early neuronal survival, regulation of axonal
transport, regulation of BDNF production particularly in the
cortex, and controlling synaptic activity (Zuccato et al., 2010).
Given the role of miR-137 in neuronal development these two
molecules may work in concert to regulate this process. Further
research will be necessary to determine if HTT plays a role in
schizophrenia.
By IPA analysis of the putative and experimentally validated tar-
gets of miR-137, we identified that a large majority are expressed
in the NS, forming networks involving genes associated with schiz-
ophrenia. The top canonical pathways identified by these analyses
are widely known to be associated with learning and memory
and synaptic formation, suggesting that the genetic impact of this
miRNA may play a role in the processes of cognition and neu-
ronal development. While our own analyses and the results of the
literature support a role of miR-137 in the etiology of schizophre-
nia, further analysis is necessary to understand the full impact of
this miRNA. In particular, it will be important to evaluate the
involvement of LTP, ephrin receptor signaling, axonal guidance,
and glutamate signaling. Further elucidation of the role of miR-
137 in schizophrenia is merited as the negative symptoms and
cognitive deficits associated are still inadequately treated and can
have such a grave impact on patients. This miRNA may provide a
new avenue for exploring the underlying mechanisms involved in
the etiology of the disease as well as discovering new biomarkers
and therapeutic targets.
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Table S1 | miR-137 putative target list, chromosomal locations and disease
associations.
Figure S1 | miR-137 targets in Sertoli cell-signaling canonical pathway.
Figure shows the Sertoli cell-signaling pathway from IPA with the symbols for all
miR-137 putative and verified targets shown in orange.
Figure S2 | miR-137 targets in agrin interaction at the neuromuscular
junction canonical pathway. Figure shows the agrin interaction at the
neuromuscular junction pathway from IPA with the symbols for all miR-137
putative and verified targets shown in orange.
Figure S3 | miR-137 targets in synaptic long-term potentiation (LTP)
canonical pathway. Figure shows the synaptic LTP pathway from IPA with the
symbols for miR-137 putative and verified targets shown in orange.
Figure S4 | miR-137 targets in ephrin receptor signaling canonical
pathway. Figure shows the ephrin receptor signaling pathway from IPA with
the symbols for all miR-137 putative and verified targets shown in orange.
Figure S5 | miR-137 targets in axonal guidance canonical pathway. Figure
shows the axonal guidance pathway from IPA with the symbols for all miR-137
putative and verified targets shown in orange.
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